Related Experiment Videos

Analysis of low natural killer cell activity in 89Sr-treated mice

Insights

Strontium-89 (89Sr) treatment reduces natural killer cell activity by damaging bone marrow, not by introducing suppressor cells. This impairment stems from the destruction of the bone marrow microenvironment essential for natural killer cell development.

Area of Science:

  • Immunology
  • Radiobiology
  • Oncology

Background:

  • Strontium-89 (89Sr) is a bone-seeking radioisotope used in cancer therapy.
  • 89Sr treatment selectively irradiates bone marrow, leading to reduced natural killer cell activity against YAC-1 lymphoma (NK(YAC-1)).

Purpose of the Study:

  • To investigate whether cellular suppressors are responsible for the diminished NK(YAC-1) activity observed in 89Sr-treated mice.
  • To elucidate the mechanism behind the reduced NK(YAC-1) function post-89Sr administration.

Main Methods:

  • In vitro assays mixing spleen cells from 89Sr-treated and normal mice to assess NK(YAC-1) inhibition.
  • In vivo studies involving adoptive transfer of spleen cells and assessment of lung clearance of radiolabeled YAC-1 cells.
  • Evaluation of NK(YAC-1) activity in normal spleen cells transferred into 89Sr-treated hosts.

Main Results:

  • In vitro spleen cell mixing did not reveal specific inhibition of NK(YAC-1) activity.
  • In vivo lung clearance assays showed impaired NK(YAC-1) activity in 89Sr-treated mice.
  • Adoptive transfer experiments indicated no suppressor cell activity from 89Sr-treated spleen cells, nor suppression of transferred normal cells within 89Sr-treated hosts.

Conclusions:

  • The reduction in NK(YAC-1) activity following 89Sr treatment is not mediated by suppressor cells.
  • The impaired natural killer cell function is likely a consequence of the destruction of the bone marrow microenvironment, crucial for NK cell generation.

Related Concept Videos